Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;53(5):329-342.
doi: 10.1159/000533330. Epub 2023 Sep 13.

Standardization of Nomenclature for the Mechanisms and Materials Utilized for Extracorporeal Blood Purification

Collaborators, Affiliations
Review

Standardization of Nomenclature for the Mechanisms and Materials Utilized for Extracorporeal Blood Purification

Thiago Reis et al. Blood Purif. 2024.

Abstract

In order to develop a standardized nomenclature for the mechanisms and materials utilized during extracorporeal blood purification, a consensus expert conference was convened in November 2022. Standardized nomenclature serves as a common language for reporting research findings, new device development, and education. It is also critically important to support patient safety, allow comparisons between techniques, materials, and devices, and be essential for defining and naming innovative technologies and classifying devices for regulatory approval. The multidisciplinary conference developed detailed descriptions of the performance characteristics of devices (membranes, filters, and sorbents), solute and fluid transport mechanisms, flow parameters, and methods of treatment evaluation. In addition, nomenclature for adsorptive blood purification techniques was proposed. This report summarizes these activities and highlights the need for standardization of nomenclature in the future to harmonize research, education, and innovation in extracorporeal blood purification therapies.

Keywords: Clearance; Dialysis; Filtration; Flux; Membrane characteristics; Renal replacement therapy.

PubMed Disclaimer

Conflict of interest statement

T.R. has received funding for lectures and has been consultant or advisory board member for AstraZeneca, B. Braun, Baxter, bioMérieux, Boehringer Ingelheim, Contatti (CytoSorbents), Eurofarma, Lifepharma, Medcorp, Medtronic, and Nova Biomedical. D.E.S., W.C., S.D.R., A.L., Z.R., J.A.K., and R.M. declare no competing interests. L.G.F. has received research support and lecture fees from Ortho Clinical Diagnostics, Baxter, ExThera, and bioMérieux and consulting fees from La Jolla Pharmaceuticals and Paion. G.V. has received lectures fees from Baxter. C.R. has been on the advisory board or speaker’s bureau for Asahi, Aferetica, AstraZeneca, Baxter, bioMérieux, CytoSorbents, GE, Jafron, Medica, and Medtronic. M.H.R. has received funding for lectures and has been consultant or advisory board member for AstraZeneca, Baxter, Reata, and Tavere.

References